




RealRate

PHARMACEUTICAL 2017

Tvardi Therapeutics Inc
Rank 144 of 308



The relative strengths and weaknesses of Tvardi Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tvardi Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Tvardi Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 268%, being 24% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	61,445
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,533
Liabilities, Non-Current	0
Other Assets	769
Other Compr. Net Income	38
Other Expenses	-468
Other Liabilities	0
Other Net Income	652
Other Revenues	86
Property and Equipment	1,614
Research and Development	49,253
Selling, General and Administrative Expense	9,233

Output Variable	Value in 1000 USD
Assets	63,828
Liabilities	11,533
Expenses	58,018
Revenues	86
Stockholders Equity	52,295
Net Income	-57,280
Comprehensive Net Income	-57,261
BaseVar	67,078
ECR before LimitedLiability	151%
Economic Capital Ratio	268%